Please login to the form below

Not currently logged in
Email:
Password:

South Africa to develop HIV, TB and malaria vaccines

South Africa's President, Thabo Mbeki, opens the third branch of the International Centre for Genetic Engineering and Biotechnology in Cape Town

South Africa's President, Thabo Mbeki, has opened the third branch of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Cape Town, according to local media reports.

The centre will conduct vaccine R&D for HIV, malaria, tuberculosis and other infectious diseases affecting the country.

South Africa has spent ZAR 40m (USD 5.6m) on the ICGEB lab, which is located at the University of Cape Town's Institute of Infectious Diseases and Molecular Medicine.

As South Africa's funds were only sufficient to establish three research groups, President Mbeki challenged the international community to donate up to ZAR 120m (USD 17m), which would help to fund seven research programmes slated for a 2010 launch.

Mbeki also invited potential partners to assist and work with the ICGEB to ensure that it realised its objectives.

Nigeria and Tanzania lost out in competitive bids to host the African branch of ICGEB. The other ICGEB sites are located in Trieste, Italy, and New Delhi, India.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics